CO5640102A2 - Composiciones farmaceuticas de agonista parcial de 5ht4 - Google Patents

Composiciones farmaceuticas de agonista parcial de 5ht4

Info

Publication number
CO5640102A2
CO5640102A2 CO04067463A CO04067463A CO5640102A2 CO 5640102 A2 CO5640102 A2 CO 5640102A2 CO 04067463 A CO04067463 A CO 04067463A CO 04067463 A CO04067463 A CO 04067463A CO 5640102 A2 CO5640102 A2 CO 5640102A2
Authority
CO
Colombia
Prior art keywords
composition according
partial agonist
weight
pharmaceutical compositions
percent
Prior art date
Application number
CO04067463A
Other languages
English (en)
Spanish (es)
Inventor
Jerome Aubert
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5640102A2 publication Critical patent/CO5640102A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO04067463A 2001-12-21 2004-07-15 Composiciones farmaceuticas de agonista parcial de 5ht4 CO5640102A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (1)

Publication Number Publication Date
CO5640102A2 true CO5640102A2 (es) 2006-05-31

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04067463A CO5640102A2 (es) 2001-12-21 2004-07-15 Composiciones farmaceuticas de agonista parcial de 5ht4

Country Status (31)

Country Link
US (2) US20050106236A1 (enExample)
EP (2) EP1321142A1 (enExample)
JP (1) JP4718776B2 (enExample)
KR (1) KR100980144B1 (enExample)
CN (1) CN100464749C (enExample)
AR (1) AR037937A1 (enExample)
AT (1) ATE320807T1 (enExample)
AU (1) AU2002361198B2 (enExample)
BR (1) BR0215148A (enExample)
CA (1) CA2470668C (enExample)
CO (1) CO5640102A2 (enExample)
CY (1) CY1105559T1 (enExample)
DE (1) DE60210139T2 (enExample)
DK (1) DK1458377T3 (enExample)
EC (1) ECSP105163A (enExample)
EG (1) EG24194A (enExample)
ES (1) ES2258171T3 (enExample)
HU (1) HU226589B1 (enExample)
IL (2) IL162451A0 (enExample)
MX (1) MXPA04006157A (enExample)
MY (1) MY139546A (enExample)
NO (1) NO20042779L (enExample)
NZ (1) NZ533585A (enExample)
PE (1) PE20030872A1 (enExample)
PL (1) PL369509A1 (enExample)
PT (1) PT1458377E (enExample)
RU (1) RU2322978C2 (enExample)
SI (1) SI1458377T1 (enExample)
TW (1) TWI260221B (enExample)
WO (1) WO2003053432A1 (enExample)
ZA (1) ZA200404467B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004007105T2 (de) 2003-01-28 2008-02-28 Microbia Inc., Cambridge Zusammensetzung zur behandlung von gastrointestinalen störungen
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2004104577A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
PT1663182E (pt) 2003-09-12 2013-03-14 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
US20050165085A1 (en) * 2003-12-16 2005-07-28 Marioara Mendelovici Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP3351248B1 (en) 2008-12-31 2021-06-09 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102287207B1 (ko) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス, インコーポレイテッド Nhe媒介性アンチポートの阻害薬
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd 1−アザビシクロ[3.3.0]オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
DE60039357D1 (de) * 1999-08-03 2008-08-14 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil

Also Published As

Publication number Publication date
DE60210139D1 (de) 2006-05-11
CA2470668A1 (en) 2003-07-03
NZ533585A (en) 2006-04-28
KR100980144B1 (ko) 2010-09-03
IL162451A0 (en) 2005-11-20
JP4718776B2 (ja) 2011-07-06
ECSP105163A (es) 2010-07-30
AU2002361198A1 (en) 2003-07-09
NO20042779L (no) 2004-09-17
AU2002361198B2 (en) 2006-06-08
SI1458377T1 (sl) 2006-08-31
EP1458377B1 (en) 2006-03-22
JP2005516946A (ja) 2005-06-09
RU2004122631A (ru) 2005-08-10
DK1458377T3 (da) 2006-06-12
ZA200404467B (en) 2006-05-31
KR20040066922A (ko) 2004-07-27
HUP0402492A3 (en) 2008-04-28
MY139546A (en) 2009-10-30
EG24194A (en) 2008-10-14
IL162451A (en) 2009-02-11
HU226589B1 (en) 2009-04-28
EP1458377A1 (en) 2004-09-22
TWI260221B (en) 2006-08-21
EP1321142A1 (en) 2003-06-25
WO2003053432A1 (en) 2003-07-03
US20090104263A1 (en) 2009-04-23
CN100464749C (zh) 2009-03-04
PE20030872A1 (es) 2003-11-24
PL369509A1 (en) 2005-04-18
MXPA04006157A (es) 2004-10-27
TW200410684A (en) 2004-07-01
CN1606438A (zh) 2005-04-13
HUP0402492A2 (hu) 2005-07-28
DE60210139T2 (de) 2006-08-17
US20050106236A1 (en) 2005-05-19
ES2258171T3 (es) 2006-08-16
AR037937A1 (es) 2004-12-22
PT1458377E (pt) 2006-07-31
CA2470668C (en) 2011-07-05
ATE320807T1 (de) 2006-04-15
RU2322978C2 (ru) 2008-04-27
BR0215148A (pt) 2004-10-19
CY1105559T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
CO5640102A2 (es) Composiciones farmaceuticas de agonista parcial de 5ht4
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
HRP20090381T1 (en) Compositions comprising drospirenone molecularly dispersed
PA8586401A1 (es) 4-piperazinilbencenosulfonilindoles y uso de los mismos
DE60330187D1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
EA200701357A1 (ru) Композиции и способы применения модулятора рецептора 5ht
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
NO20043367L (no) Oralt farmasoytisk preparat
CA2505964A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
CO5390076A1 (es) Composiciones farmaceuticas
TW200517106A (en) Sustained release pharmaceutical compositions
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
BRPI0417810B8 (pt) arilpirazóis substituídos como agentes parasiticidas, composição veterinária e uso dos mesmos
BRPI0413676A (pt) composto, e, composição farmacêutica
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
GB2421241A (en) Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
TN2010000129A1 (fr) Nouvelles compositions a base de taxoides
EA200400848A1 (ru) Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов
CY1113164T1 (el) Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
ATE301463T1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist

Legal Events

Date Code Title Description
FC Application refused